A first-in-human, gene-silencing treatment for Alzheimer’s disease with Catherine Mummery

Written by Sharon Salt, Editor

Genetic therapies are becoming a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. Since the groundbreaking results from IONIS-HTTRx (RG6042) for Huntington’s disease were announced, researchers across the globe have been working to translate gene-based approaches to other neurodegenerative diseases such as Alzheimer’s. In particular, the Neurogenetic Therapies Programme at University College London (UK) aims to facilitate drug discovery right from pre-clinical work in genetic therapies to first-in-man clinical trials. We recently spoke with Catherine Mummery, who is a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (London, UK), at the Wolfson Closing Symposium (19 June 2019,...

To view this content, please register now for access

It's completely free